SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2005
CYTRX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| |
|
|
000-15327
(Commission File Number)
|
|
58-1642740
(I.R.S. Employer Identification No.) |
|
|
|
|
11726 San Vicente Boulevard, Suite 650
Los Angeles, California
(Address of Principal Executive Offices)
|
|
90049
(Zip Code) |
(310) 826-5648
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the Registrant under any of the following provisions (See General Instruction
A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 8.01 Other Events.
On September 30, 2005, CytRx Corporation completed the merger of CytRx Laboratories, Inc. into
CytRx Corporation. Prior to the merger, CytRx Laboratories was the wholly-owned subsidiary of
CytRx Corporation. As a result of the merger, all of the assets and liabilities of CytRx
Laboratories became the assets and liabilities, respectively, of CytRx Corporation. No securities
of CytRx Corporation were issued and no other consideration was paid by CytRx Corporation in
connection with the merger.